CN106266037B - Liquid gel and preparation method thereof - Google Patents
Liquid gel and preparation method thereof Download PDFInfo
- Publication number
- CN106266037B CN106266037B CN201610694663.7A CN201610694663A CN106266037B CN 106266037 B CN106266037 B CN 106266037B CN 201610694663 A CN201610694663 A CN 201610694663A CN 106266037 B CN106266037 B CN 106266037B
- Authority
- CN
- China
- Prior art keywords
- parts
- gel
- chitosan
- hyaluronic acid
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 10
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000001879 gelation Methods 0.000 title description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 16
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229960005040 miconazole nitrate Drugs 0.000 claims abstract description 15
- 239000008213 purified water Substances 0.000 claims abstract description 13
- 239000000126 substance Substances 0.000 claims abstract description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 12
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 12
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 12
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 10
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 10
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 10
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 10
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 10
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 10
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 10
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 10
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 10
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 10
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 9
- 229960001631 carbomer Drugs 0.000 claims abstract description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 9
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract description 9
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 7
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 7
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 241001092040 Crataegus Species 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 6
- 230000008961 swelling Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 14
- 240000000171 Crataegus monogyna Species 0.000 abstract 1
- 210000001215 vagina Anatomy 0.000 description 8
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 201000008100 Vaginitis Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000005000 reproductive tract Anatomy 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 208000007313 Reproductive Tract Infections Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical group [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A61K31/78—Polymers containing oxygen of acrylic acid or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A liquid gel and a preparation method thereof are characterized in that: the gel comprises the following components: 0.5-2.5 parts of chitosan, 0.5-5 parts of hydroxypropyl methylcellulose, 60000.5-6 parts of polyethylene glycol, 0.1-0.3 part of chlorhexidine acetate, 0.1-3 parts of carbomer, 0.1-2 parts of propylene glycol, 0.1-3 parts of hawthorn seed, 0.2-2 parts of hyaluronic acid substances, 0.01-0.5 part of miconazole nitrate, 50-70 parts of purified water and 5-7.5 of pH value. Has the advantages of small side effect, good curative effect, difficult causing the germ flora to be unbalanced, and being capable of effectively relieving or curing the illness.
Description
Technical Field
The invention relates to the technical field of gel materials, in particular to a liquid gel and a preparation method thereof.
Background
With changes in life concepts and deterioration of the surrounding environment, genital tract infections are becoming more and more common and frequently occurring in women. It is a type of infectious disease that occurs primarily in the female reproductive system, and is transmitted primarily through the sexual pathway, with vaginitis being the most common. If oral medication is adopted for treatment, the side effect is large on the first time, and the second time can not directly act on the affected part, so the curative effect is not obvious; at present, gel materials are also directly used for acting on affected parts, so that the effect is quick and the curative effect is obvious, but certain defects still exist: for example, the large content of chemical components still has large side effects, and in addition, vaginal flora imbalance is easily caused, and the disease condition can not be effectively relieved or cured.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides the liquid gel which has small side effect and good curative effect, is not easy to cause the imbalance of the genital tract flora, and can effectively relieve or cure the illness state.
In order to solve the technical problems, the invention adopts the technical scheme that: a liquid gel, the gel comprising the components: 0.5-2.5 parts of chitosan, 0.5-5 parts of hydroxypropyl methylcellulose, 60000.5-6 parts of polyethylene glycol, 0.1-0.3 part of chlorhexidine acetate, 0.1-3 parts of carbomer, 0.1-2 parts of propylene glycol, 0.1-3 parts of hawthorn seed, 0.2-2 parts of hyaluronic acid substances, 0.01-0.5 part of miconazole nitrate, 50-70 parts of purified water and 5-7.5 of pH value.
Further preferably, the liquid gel of the present invention comprises the following components: 1-2 parts of chitosan, 1-4 parts of hydroxypropyl methylcellulose, 01-3 parts of polyethylene glycol 60001, 0.15-0.25 part of chlorhexidine acetate, 0.15-2 parts of carbomer, 0.5-1 part of propylene glycol, 0.5-2 parts of hawthorn seed, 0.5-1.5 parts of hyaluronic acid substances, 0.02-0.3 part of miconazole nitrate, 55-65 parts of purified water and 5-7.5 of pH value.
The hyaluronic acid substance is sodium hyaluronate.
The invention also provides a preparation method of the liquid gel, which comprises the following preparation steps:
(1) dissolving chitosan in purified water according to a formula ratio, and fully swelling for later use;
(2) dissolving the hyaluronic acid substances in purified water according to the formula proportion, and fully swelling for later use;
(3) mixing the rest other components in the formula proportion uniformly;
(4) and (3) adding the solution obtained in the steps (1) to (3) into the same container, fully stirring and uniformly mixing, and adjusting the pH value to 5-7.5 to obtain a gel product.
The invention has the advantages and beneficial effects that:
1. the invention uses the chitosan and the miconazole nitrate at the same time for the first time, the chitosan has the characteristics of broad-spectrum antibiosis, no drug resistance, strong bactericidal capability, no irritation to vagina and the like, the side effect is small, the drug effect is fully improved by combining the miconazole nitrate for the simultaneous use, and the miconazole nitrate is a broad-spectrum antifungal drug, has the antibacterial effect on various fungi, especially candida, and also has the antibacterial effect on certain gram-positive bacilli and cocci. The action mechanism is to inhibit the synthesis of fungal cell membrane and influence the metabolic process.
2. The hawthorn seeds and carbomer are used in the product, so that the ecological balance and the stable pH of microorganisms in the genital tract can be fully realized, the resistance of the vagina to various pathogenic conditions is improved, the invasion of external bacteria or pathogenic organisms by people is effectively prevented, and the resistance to the bacteria is further improved; the carbomer can adsorb and wrap inactivated HPV (human papilloma virus) to be discharged out of a body, accelerate the rapid repair and regeneration of an erosion tissue and promote healing, and the hawthorn kernels and the like can improve the peculiar smell of the vagina, improve the microenvironment of the vagina, relieve the inflammatory reaction of the vagina, reduce the amount of vaginal secretion, effectively improve the vaginal cleanliness, reduce the pH value of the vagina and effectively treat gynecological diseases such as cervicitis, cervical erosion and the like.
Detailed Description
The present invention will be described in further detail with reference to the following examples, but the present invention is not limited to the following examples.
Example 1
The gel comprises the following components: 2 parts of chitosan, 2 parts of hydroxypropyl methylcellulose, 2 parts of polyethylene glycol 60002, 0.2 part of chlorhexidine acetate, 0.15 part of carbomer, 0.15 part of propylene glycol, 2 parts of hawthorn seeds, 1.5 parts of hyaluronic acid substances, 0.02 part of miconazole nitrate, 55 parts of purified water and 6.5 of pH value.
The method comprises the following specific steps:
(1) dissolving chitosan in purified water according to a formula ratio, and fully swelling for later use;
(2) dissolving the hyaluronic acid substances in purified water according to the formula proportion, and fully swelling for later use;
(3) mixing the rest other components in the formula proportion uniformly;
(4) and (3) adding the solution obtained in the steps (1) to (3) into the same container, fully stirring and uniformly mixing, and adjusting the pH value to obtain a gel product.
The sum of the water consumption of the steps (1) and (2) is the water consumption of the total purified water in the gel formula.
Example 2
The gel comprises the following components: 1.5 parts of chitosan, 1 part of hydroxypropyl methylcellulose, 60001 parts of polyethylene glycol, 0.2 part of chlorhexidine acetate, 0.3 part of carbomer, 0.8 part of propylene glycol, 1 part of hawthorn kernel, 1 part of hyaluronic acid substances, 0.025 part of miconazole nitrate, 60 parts of purified water and the pH value of 77.
The procedure is as in example 1.
Example 3
The gel comprises the following components: 2 parts of chitosan, 3 parts of hydroxypropyl methylcellulose, 60002.5 parts of polyethylene glycol, 0.20 part of chlorhexidine acetate, 0.20 part of carbomer, 0.6 part of propylene glycol, 0.6 part of hawthorn kernel, 1.0 part of hyaluronic acid substances, 0.05 part of miconazole nitrate, 55 parts of purified water and the pH value of 6.
The procedure is as in example 1.
Comparative example
The miconazole nitrate in the gel was removed, and the other components were not changed from those in example 3, and the procedure was the same as in example 1.
The sample prepared by the embodiment of the invention has the following using effects: volunteers were divided into 3 groups of 80 persons each on average. The first group (test group) of volunteers washed their vagina with warm boiled water every night, 3g of the gel prepared in example 1 was applied around labia and inside the vagina; in the second group (control group), commercial vaginitis antibacterial gel is used as a control, and the dosage is 3g each time; each group was administered for two weeks and then first and fifth weeks before second review; in the third group (comparative group), 3g of the antibacterial gel for vaginitis is taken as a control; the first review was performed two weeks after each group was administered continuously and the results of the second review after five weeks are shown in table 1.
TABLE 1 comparison of clinical efficacy of two groups of patients
| Group of | N | Cure of disease | Show effect | Invalidation | Total effective rate |
| Observation group | 80 | 68 | 10 | 2 | 97.5％ |
| Control group | 80 | 50 | 8 | 22 | 72.5％ |
| Comparative example group | 80 | 65 | 8 | 15 | 91.25％ |
As can be seen from the table above, the gel prepared by the invention has the advantages of high cure rate and good curative effect; and the effect difference of the chitosan and the miconazole nitrate is obvious when the chitosan and the miconazole nitrate are used simultaneously, which proves that the cure rate is higher when the chitosan and the miconazole nitrate are used simultaneously.
Claims (2)
1. A liquid gel characterized by: the gel comprises the following components: 0.5-2.5 parts of chitosan, 0.5-5 parts of hydroxypropyl methylcellulose, 60000.5-6 parts of polyethylene glycol, 0.1-0.3 part of chlorhexidine acetate, 0.1-3 parts of carbomer, 0.1-2 parts of propylene glycol, 0.1-3 parts of hawthorn seed, 0.2-2 parts of hyaluronic acid substances, 0.01-0.5 part of miconazole nitrate, 50-70 parts of purified water and 5-7.5 of pH value;
the preparation method comprises the following steps:
(1) dissolving chitosan polymer in water, and fully swelling for later use;
(2) adding hyaluronic acid substances into water, and fully swelling for later use;
(3) mixing other components uniformly;
(4) and (3) adding the solution obtained in the steps (1) to (3) into the same container, fully stirring and uniformly mixing, and adjusting the pH value to 5-7.5 to obtain a gel product.
2. The liquid gel of claim 1, wherein: the gel comprises the following components: 1-2 parts of chitosan, 1-4 parts of hydroxypropyl methylcellulose, 0.5-1 part of propylene glycol, 0.5-2 parts of hawthorn kernel, 0.5-1.5 parts of hyaluronic acid substances, 0.02-0.3 part of miconazole nitrate, 55-65 parts of purified water and 5-7.5 of pH value, wherein the hydroxypropyl methylcellulose is added into the mixture, and the mixture is stirred for a while.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610694663.7A CN106266037B (en) | 2016-08-19 | 2016-08-19 | Liquid gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610694663.7A CN106266037B (en) | 2016-08-19 | 2016-08-19 | Liquid gel and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106266037A CN106266037A (en) | 2017-01-04 |
| CN106266037B true CN106266037B (en) | 2020-09-29 |
Family
ID=57661720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610694663.7A Expired - Fee Related CN106266037B (en) | 2016-08-19 | 2016-08-19 | Liquid gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106266037B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107080733A (en) * | 2017-04-17 | 2017-08-22 | 滨州医学院附属医院 | A kind of miconazole nitrate chitosan vagina slowly-releasing gel and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422448A (en) * | 2008-12-10 | 2009-05-06 | 李海涛 | Miconazole nitrate film and preparation method and pharmacy use thereof |
| CN102626524A (en) * | 2012-05-04 | 2012-08-08 | 江西中兴汉方药业有限公司 | Chitosan gynaecologic antibacterial gel and preparation method thereof |
| CN103316033A (en) * | 2013-07-03 | 2013-09-25 | 康晓飞 | Gel and use thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050276836A1 (en) * | 1997-06-11 | 2005-12-15 | Michelle Wilson | Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents |
-
2016
- 2016-08-19 CN CN201610694663.7A patent/CN106266037B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101422448A (en) * | 2008-12-10 | 2009-05-06 | 李海涛 | Miconazole nitrate film and preparation method and pharmacy use thereof |
| CN102626524A (en) * | 2012-05-04 | 2012-08-08 | 江西中兴汉方药业有限公司 | Chitosan gynaecologic antibacterial gel and preparation method thereof |
| CN103316033A (en) * | 2013-07-03 | 2013-09-25 | 康晓飞 | Gel and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106266037A (en) | 2017-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8765819B2 (en) | Composition comprising benzoic acid in combination with organic acid preservatives as active ingredients and the use thereof | |
| CN110464811A (en) | A kind of gynaecology's foam antibacterial liquid and preparation method thereof | |
| CN104224923A (en) | Tea tree essential oil antimicrobial gel for treating vaginal disease in gynecology | |
| AU2005257722A1 (en) | Composition comprising lactic acid and lactoferrin | |
| CN113730433B (en) | Gynecological gel for treating colpitis and preparation method and application thereof | |
| CN109771368A (en) | A kind of bacteriostatic gel and preparation method thereof | |
| CN111449973A (en) | Foaming agent for restoring microecological balance of female vagina and preparation method thereof | |
| CN108853003A (en) | A kind of Nifuratel-Nysfungin soft-capsule type suppository and preparation method thereof | |
| CN109010124B (en) | Marine refined gynecological antibacterial gel and preparation method thereof | |
| CN114652748A (en) | Preparation method and application of medical gynecological lotion containing stem cell bacteriostatic factors | |
| CN106266037B (en) | Liquid gel and preparation method thereof | |
| CN104069124B (en) | Compositions and preparation for gynecological infection | |
| CN103191408A (en) | Medicine composition and gel for treating colpitis and applications thereof | |
| CN103768089A (en) | Chitosan antibacterial lotion for gynecology and preparation method thereof | |
| WO2021036294A1 (en) | Vaginal acid-base buffer gel and preparation method | |
| CN106214882A (en) | A kind of high intensity antibacterial liquid gel and preparation method thereof | |
| CN109985037A (en) | A kind of gynecological gel | |
| CN110124017A (en) | A kind of bacteriostatic gel | |
| CN115837046A (en) | Ornidazole pessary and preparation method thereof | |
| CN113662998A (en) | A pharmaceutical composition for treating vaginitis and gynecological inflammation, and its preparation method | |
| CN101933895A (en) | Fenticonazole nitrate vaginal suppository composition | |
| CN106177274B (en) | Contraceptive gel composition and preparation method thereof | |
| CN110193004A (en) | Women bacteriostatic gel and preparation method thereof containing biological bacteriostatic peptide | |
| CN102526121A (en) | Wound repair composition and preparation method and application thereof | |
| CN108066278B (en) | Gynecological gel containing chitosan oligosaccharide and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200929 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |